Curis Sells December — and Quietly Pushes the NDA to 2028
The PCNSL response rate held up; the calendar did not. A nano-cap with $5 million of cash and a fresh October raise asks investors for one more year.
CRIS · Earnings Call · 2026-11-12
The number that actually moved
Curis reported third-quarter numbers on November 12 that, on their face, looked like the same script investors have read for six quarters: a small net loss, shrinking expenses, a rare-disease lymphoma program inching toward a filing, and a December data drop to look forward to. The response rates even improved in the telling — 86% in seven BTKi-naive PCNSL patients, 26% in 39 patients whose disease had already progressed on a BTK inhibitor.
But one number moved in the wrong direction, and it is the only one that sets the value of a pre-revenue biotech: time.
In March, Jim Dentzer told investors that the enrollment cadence placed Curis "at full enrollment with the potential to file after six months of following patients somewhere in the 2027 range" (“somewhere in the 2027 range” — James E. Dentzer, Chief Executive Officer · 2026-03-19). Two months later, the guidance was to expect "a substantial update on enrollment in the first half of 2027" (“a substantial update on enrollment” — James Dentzer, Chief Executive Officer · 2026-05-13).
On this call, asked directly when the registrational study fills and when the data land, the answer had quietly slid a year:
we would anticipate a full enrollment in 2027 and assuming that, that happens, filing it in 2028.
That is the story. Nothing broke — but the clock was reset, and the clock is the asset.
The clinical case is intact, and that's the tension
The efficacy narrative is genuinely better than the calendar. The naive patient cohort at 6 of 7 responding compares favorably against the 39%–67% range management cites for BTK inhibitors alone in PCNSL, and the salvage line patients — patients who progressed on a BTK inhibitor and often go straight to hospice — produced 10 responders out of 39. That is the kind of updated data set that supports an accelerated approval path, and management knows exactly where the bar sits: “we only need a handful more patients, 10 to 15 more patients is what we're looking to get. And only a couple of responses are needed in order to hit the hurdle. As you know, our hurdle is generally a 20% ORR, and we've been running better than that so far.” — James Dentzer, Likely Executive or Senior Management (possibly CEO or Head of Clinical Development) · 2026-11-12
So why the slip? Because the disease is vanishingly rare and the enrollment language has not changed in a year: “the enrollment, as you know, has been choppy because it's very hard to find these patients. It is an ultra-orphan disease.” — James Dentzer, Likely Executive or Senior Management (possibly CEO or Head of Clinical Development) · 2026-11-12 The word "choppy" (and "lumpy" in prior calls) has now survived four consecutive transcripts. What is new is that the residual uncertainty has been reframed — not "will the response rate hold" but "when do the last three of the last fifteen patients respond," since duration of response cannot be packaged for the FDA until the last patient is in and followed.
What management stopped talking about
Loudest in this transcript is a word that isn't in it: AML. In the March call the CEO was explicit — “we are definitely prioritizing NHL ahead of AML” — James E. Dentzer, Chief Executive Officer · 2026-03-19 — and in May a partnership question on the AML program was deflected toward generating data in the lymphoma indications. The company's own keyword history carries quarters of frontline AML, Triplet Study and FLT3 inhibitor weight through 2024 and early 2025. In this call, the third program simply evaporates. That is a real signal, not boilerplate: Curis is now a two-asset story, and the smaller of those two assets is being marketed as the option.
That option is CLL. Eleven sites, twelve patients, data by year-end — and the December readout has been the promised catalyst since March. What has changed is the specificity. In March, Dr. Hamdy was “quite hopeful that by ASH we will have some meaningful data to present” — Ahmed M. Hamdy, Medical Officer · 2026-03-19. On this call, asked what the release would actually contain, the answer was “exactly which data we're going to be presenting, I'll hold that for the presentation” — James Dentzer, Likely Executive or Senior Management (possibly CEO or Head of Clinical Development) · 2026-11-12 — with the only concrete tell being that investigators will be watching for lymphocytosis and any sign of tumor reduction. The dual blockade thesis (BTK inhibition of the BCR pathway plus emavusertib on the TLR pathway, driving deeper undetectable disease) remains the most interesting thing in the story, but the data in CLL is now a December binary, not a slope.
The balance sheet is the real clock
Curis ended September with $5 million in cash and roughly 4.1 million shares, and management says the October financing carries it “into '27” — Diantha Duvall, Likely Investor Relations or Communications · 2026-11-12. That is not a runway; it is a bridge to the next raise. effective net cash has collapsed to about $6 million, down more than 98% from its 2021 peak, and the solvency picture looks worse once burn is annualized — cash runway stood at well under one quarter at the Q2 filing.
The cost side tells you how the company has been surviving: R&D has ground steadily lower to roughly $7 million a quarter, and the explanation offered each period is the recurring lower employee related costs keyword that has appeared in nearly every quarter of the last two years. It is real discipline, and it is also a decade-long compression of a company that has never had the balance sheet to run a registrational study comfortably. the quarterly net loss still runs near $9 million, and the per-share math is the tell: the nine-month loss per share moved from $43.82 to $16.77 while the dollar loss grew from $26.9 million to $40.9 million. That gap is dilution, and it is why the December data and the 2027 enrollment target are not intellectual events for this shareholder base.
The tape already prices a coin flip
Before this print, the stock had fallen roughly 89% over ninety trading days from a June 30 peak near $10.30 — then snapped back about 174% in the final nine sessions into the report. Names like this are being sold across the complex; the broader market's ninety-day laggards include small molecule drug exposure trading down nearly 40%. A nano-cap that has lost effectively all of its value since 2012 does not need a good quarter. It needs a good December, and then a financing that doesn't erase the December.
That is the honest read of this call: better data, worse timing, thinner balance sheet, and a management team that is now managing a clock it does not control. The real question is no longer whether emavusertib works in PCNSL. It is whether Curis can afford to be right slowly.